Table 2.

Pamiparib and TMZ Combination in Glioblastoma and SCLC Cells.

Cell lines		EC50 of TMZ single agent (µM)	% of cells with EOB	Average EOB per cell	EC50 of TMZ + pamiparib @ nM (µM)	Max EC50 shift for TMZ
GBM cell lines	SNB-19	>300	95%	34.7	9.1 µM@3µM	>33 fold ↓
	SF-295	>300	80%	36.9	10.5 µM@3µM	>29 fold ↓
	T98G	>300	55%	26.9	37.0 µM@3µM	>8 fold ↓
	SF-539	80	80%	19.9	10.2 µM@3µM	8 fold ↓
	U-118MG	>300	70%	24.0	42.0 µM@3µM	>7 fold ↓
	U251	32	80%	20.7	5.1 µM@3µM	6 fold ↓
	LN-229	>300	45%	10.6	55.2 µM@1µM	>5 fold ↓
	U87-MG	>300	50%	10.7	N.A.	N.A.
SCLC cell lines	NCI-H2227	576	75%	22.9	19.2 µM@3µM	30 fold ↓
	DMS153	60	35%	25.7	2.3 µM@3µM	26 fold ↓
	NCI-H1048	153	55%	18.6	6.3 µM@1µM	24 fold ↓
	NCI-H209	63	20%	4.6	13.8 µM@1µM	5 fold ↓
	NCI-H1436	>300	15%	∼1.0	N.A.	N.A.
	NCI-H2286	182	25%	5.6	N.A.	N.A.
	NCI-H69	15	0	∼13.8	N.A.	N.A.